Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Miriam T. Jacobs, Michael D. Jain, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph McGuirk, Abhinav Deol, Alison Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier Munoz, Julio C. Chavez, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Armin Ghobadi, Frederick L. Locke
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:753-759
The majority of patients with large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, develop cytokine release syndrome (CRS). Whether the lack of development of CRS with axi-
Autor:
Efstratios Koutroumpakis, Raphael E Steiner, Sairah Ahmed, Michael Wang, Loretta J. Nastoupil, Nicolas Palaskas, Catherine M. Claussen, Jason R. Westin, Paolo Strati, Anita Deswal, Chelsea C. Pinnix, Jose Banchs, Lei Feng, Elizabeth J. Shpall, Francisco Vega, Cristina Gutierrez, Kaveh Karimzad, Sattva S. Neelapu, Gabriela Rondon, Melody R. Becnel
Publikováno v:
Haematologica. 107:1555-1566
Standard of care (SOC) chimeric antigen receptor (CAR) T-cell therapies such as axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are associated with multisystem toxicities. There is limited information available about cardiovascular
Autor:
Abhinav Deol, Amanda F. Cashen, N. Nora Bennani, Khoan Vu, Michael D. Jain, David B. Miklos, Sattva S. Neelapu, Brian T. Hill, Jason R. Westin, Julie M. Vose, Alison R. Sehgal, Julio C. Chavez, Aaron P. Rapoport, Lazaros J. Lekakis, Andre Goy, Patrick M. Reagan, Javier Munoz, Joseph P. McGuirk, Loretta J. Nastoupil, Lei Feng, Olalekan O. Oluwole, Saurabh Dahiya, Jay Y. Spiegel, Frederick L. Locke, Charalambos Andreadis, Yi Lin, Matthew A. Lunning, Armin Ghobadi
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 27
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell lymphoma (LBCL) on the basis of the single-arm phase II ZUMA-1 trial, which showed b
Autor:
Paolo Strati, Andrew P. Jallouk, Ryan Sun, Jaihee Choi, Kaberi Das, Hua-Jay Cherng, Sairah Ahmed, Hun J. Lee, Swaminathan P. Iyer, Ranjit Nair, Loretta J. Nastoupil, Raphael E. Steiner, Chad D. Huff, Yao Yu, Haleigh Mistry, Brittany Pulsifer, Mansoor Noorani, Neeraj Saini, Elizabeth J. Shpall, Partow Kebriaei, Christopher R. Flowers, Jason R. Westin, Michelle A. T. Hildebrandt, Sattva S. Neelapu
Publikováno v:
Leukemia
Conditioning chemotherapy (CCT) has been shown to be essential for optimal efficacy of chimeric antigen receptor (CAR) T-cell therapy. Here, we determined whether the change in absolute lymphocyte count, referred to as delta lymphocyte index (DLIx),
Autor:
Paolo Strati, Sandra B. Horowitz, Luis Fayad, Hun J. Lee, Victor E. Mulanovich, Swapna Johncy, Sairah Ahmed, Sherry Adkins, Ankur Varma, Felipe Samaniego, Nathan Fowler, Sara Arafat, Jason R. Westin, Loretta J. Nastoupil, Ella Ariza Heredia, Fredrick B. Hagemeister, Yiming Chen, Sattva S. Neelapu, Partow Kebriaei
Publikováno v:
Haematologica
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients with relapsed or refractory la
Autor:
Ajlan Al Zaki, Lei Feng, Grace Watson, Sairah A. Ahmed, Haleigh Mistry, Loretta J. Nastoupil, Misha Hawkins, Ranjit Nair, Swaminathan P. Iyer, Hun J. Lee, Raphael E. Steiner, Christopher R. Flowers, Elizabeth J. Shpall, Partow Kebriaei, Sattva S. Neelapu, Jason R. Westin, Paolo Strati
Publikováno v:
Blood advances. 6(9)
About 70% of patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel) and who achieve a partial response (PR) or stable disease (SD) on the day 30 (D30) positron emission tomography (PET)–computed tomography
Several novel treatments have been approved for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) since chimeric antigen receptor T-cell (CAR-T) therapy became available. The objective of this study was to describe characteristics and tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba5f0596d5937ece74764047d835f26
Autor:
Hun Ju Lee, Swapna Johncy, Sattva S. Neelapu, Misha Hawkins, Sandra B. Horowitz, Partow Kebriaei, Ranjit Nair, Jason R. Westin, Lei Feng, Haleigh Mistry, Catherine M. Claussen, Sherry Adkins, Sairah Ahmed, Loretta J. Nastoupil, Swaminathan Padmanabhan Iyer, Nicole Johnson, Michael Wang, Fateeha Furqan, Paolo Strati, Ryan Sun, Raphael E Steiner, Felipe Samaniego, Christopher R. Flowers, Prachee Singh, Michael R. Green, Chelsea C. Pinnix, Simrit Parmar, Luis Fayad, Elizabeth J. Shpall, Maria A Rodriguez
Publikováno v:
Blood
Corticosteroids are used to treat the acute complications of chimeric antigen receptor (CAR) T-cell therapy. Strati et al examine the impact of corticosteroids on patient outcomes following CAR T-cell therapy for large B-cell lymphoma. Use of higher
Autor:
Jay Y. Spiegel, Saurabh Dahiya, Khoan Vu, Miriam T. Jacobs, Abhinav Deol, Kathleen A. Dorritie, N. Nora Bennani, Julie M. Vose, David B. Miklos, Patrick M. Reagan, Matthew A. Lunning, Armin Ghobadi, Aaron P. Rapoport, Frederick L. Locke, Loretta J. Nastoupil, Charalambos Andreadis, John S. Tamaresis, Yi Lin, Michael D. Jain, Brian T. Hill, Joseph P. McGuirk, Olalekan O. Oluwole, Sattva S. Neelapu, Andre Goy, Javier Munoz, Lazaros J. Lekakis
Publikováno v:
Blood
Autor:
Sherry Adkins, Sattva S. Neelapu, Raphael E Steiner, Bouthaina S. Dabaja, Jillian R. Gunther, Misha Hawkins, Christopher R. Flowers, Luis Fayad, Swaminathan P. Iyer, Paolo Strati, Chelsea C. Pinnix, Jason R. Westin, Ranjit Nair, Sairah Ahmed, Hun Ju Lee, M. Alma Rodriguez, Michael Wang, Loretta J. Nastoupil, Penny Fang
Publikováno v:
Strahlentherapie Und Onkologie
The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or